Vote Scores
Filings read through

How funds voted at Lineage Cell Therapeutics, Inc.

Ticker
LCTX
SEC company number
876343
Filers reporting
121, year to 30 June 2026
Latest meeting on file
Meetings on file
5

In the year to 30 June 2026, 121 filers on Form N-PX reported votes at Lineage Cell Therapeutics, Inc.. The votes fall in one meeting. The figures count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting. Filers gave 136 marks to the ballot items, each with or against management. 99.3% of the marks are with management.

On say-on-pay, 1 of the 110 reporting filers that marked the item voted against management. This is 0.9% of the filers. Of the reported shares, 0.0% went against management. The median of the 3,799 companies on this site with a say-on-pay item is 6.6% of filers and 2.9% of reported shares.

At the meeting of 10 Jun 2026, 18 fund families have a say-on-pay position with management and 0 have a position against management.

By filers reporting in the year to 30 June 2026, Lineage Cell Therapeutics, Inc. was number 3,396 of 11,972 companies with a page and votes in that year. The number of filers reporting at Lineage Cell Therapeutics, Inc. fell by 24.4% from the year to 30 June 2025 to the year to 30 June 2026. At the companies on this site with filers in both years, the total of filers reporting rose by 6.0%. In all seasons on file, category SECTION 14A SAY-ON-PAY VOTES is 26.6% of the vote records at Lineage Cell Therapeutics, Inc.. At all companies on this site, it is 12.3%.

ForAgainstAbstain, withhold or otherAmber tick: the part cast against management

If the reporting person has not received confirmation of the actual number of votes cast prior to filing a report on Form N-PX, the numbers reported may reflect the number of shares instructed to be cast. A reporting person is not required to amend a previously filed Form N-PX report if the reporting person subsequently receives confirmation of the actual number of votes cast.

The words of the SEC. Source: Form N-PX and its instructions, Special Instructions D.5 and D.8, copied on .

The words of this site: the filer writes each filing. The SEC does not say that it checked the votes. A lender does not vote shares that are on loan. A later filing (Form N-PX/A) can replace an earlier filing, and the site uses the latest.

The figures on this page count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting.

The page gives records. It gives no investment advice and no advice on how to vote.

Season on this page: year to 30 June 2026. Filings read through . How the figures are made

Since the last update

The site has recorded no change in the tracked figures of this page.

Tracked: the meetings on file and the date of the latest meeting. All recorded changes

The ballot of 10 Jun 2026

120 filers reported votes at this meeting in the year to 30 June 2026. The items are in ballot order: the company's items first, then proposals from security holders. Each bar shows how the reporting filers split. It is not the result of the meeting. The meeting page has the split by reported shares and a CSV file.

  1. Item 1: Director elections

    7 nominees. 89.1% of the reported votes are for. 1 filer withheld from or voted against at least one nominee.

    161 vote records from 13 filers. 0 of the 13 filers that marked the item voted against management.

    • Positions of 9 fund families
    • For 9
  2. Item 2: Advisory vote on executive pay (say-on-pay)

    139 vote records from 120 filers. 1 of the 110 filers that marked the item voted against management. 10 filers gave no management mark.

    • Positions of 18 fund families
    • For 18
  3. Item 3: Audit-related items (auditor ratification)

    23 vote records from 13 filers. 0 of the 13 filers that marked the item voted against management.

    • Positions of 9 fund families
    • For 9

Positions of the fund families at the meeting of 10 Jun 2026

A position is not the vote of each fund. The position of a family is the way most of the shares reported by its filers were voted. Funds of one family can vote in different ways.

KeyForAgainstAbstain or withholdSplit or no voteAgainst management

Fund families at Lineage Cell Therapeutics, Inc., meeting of 10 Jun 2026Families in name order. "Abstain" includes withhold. "Split" includes no vote. "No report" means that no filer of the family listed the item.
Fund familySay-on-pay
BlackRock and iSharesFor
BNY MellonFor
Charles SchwabFor
DimensionalFor
FidelityFor
Goldman SachsFor
Guggenheim and RydexFor
John Hancock and ManulifeFor
Lincoln FinancialFor
Morgan Stanley, Eaton Vance and CalvertFor
Neuberger BermanFor
Northern Trust and FlexSharesFor
Nuveen and TIAAFor
PGIM and PrudentialFor
SEIFor
State Street and SPDRFor
VanguardFor
Victory CapitalFor

Every meeting on file

Meetings of Lineage Cell Therapeutics, Inc., from Form N-PX filings, newest firstA meeting with 20 or more reporting filers has its own page. Dates up to three days apart count as one meeting.
MeetingSeasonFilers reportingItemsFilers against management on say-on-pay
year to 30 June 202612030.9%
year to 30 June 202515544.8%
year to 30 June 2025432not reported
year to 30 June 202416336.5%
year to 30 June 202415677.0%

Say-on-pay, season by season

Say-on-pay at Lineage Cell Therapeutics, Inc.: filers reporting on Form N-PXThe share of filers, and of the shares they reported, that voted against management.
SeasonFilers reportingFilers against managementReported shares against management
year to 30 June 20261210.9%0.0%
year to 30 June 20251604.8%1.7%
year to 30 June 20241886.5%4.6%
Lineage Cell Therapeutics, Inc. and the median of companies on this site, year to 30 June 2026
Say-on-payThis companyMedian of companies on this site
Filers against management0.9%6.6%
Reported shares against management0.0%2.9%

The median covers 3,799 companies. Each has a say-on-pay item that 20 or more filers reported. The two figures are not a grade. The median is a reference only.

Vote records at Lineage Cell Therapeutics, Inc. by category, every seasonThe category is the one each filer chose.
CategoryVote recordsShare
DIRECTOR ELECTIONS1,89053.9%
SECTION 14A SAY-ON-PAY VOTES93426.6%
AUDIT-RELATED2386.8%
CAPITAL STRUCTURE1474.2%
COMPENSATION1504.3%
CORPORATE GOVERNANCE1474.2%

The record at the SEC

Each link loaded on .

Embed this card on your site

Copy this code into your page. The card shows the figures above with their source. A line under the card links to this page.

How embedding works. It is free. Keep the link in the card and the link line under it.

Cite this page

Vote Scores. How funds voted at Lineage Cell Therapeutics, Inc.. https://votescores.com/company/lineage-cell-therapeutics-inc/. Source: SEC EDGAR, Form N-PX and N-PX/A filings read through .

Questions

How many meetings of Lineage Cell Therapeutics, Inc. are on file?
5 meetings are on file, from 6 Sep 2023 to 10 Jun 2026. 5 meetings have 20 or more reporting filers and have their own page.
Did filers report proposals from security holders at Lineage Cell Therapeutics, Inc.?
Not enough filers reported a proposal from security holders for the site to show one in the year to 30 June 2026. The ballot shows the items that filers did report.
Is this the meeting result?
No. The figures count the filers that report on Form N-PX and the shares they reported. Other holders are not in the count. Lineage Cell Therapeutics, Inc. reports the result of a vote on Form 8-K.
How does the site group meetings and names?
Filers type company names and meeting dates themselves. The site groups spellings of one company name. It treats meeting dates up to three days apart as one meeting. The data runs through 13 Nov 2026.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list Lineage Cell Therapeutics, Inc., grouped by company. The name is the most common spelling among filers. The ticker and the SEC company number come from the SEC company tickers file, matched on the exact name. The filers wrote the filings. Filings read through .